Insulin and free oestradiol are independent risk factors for benign prostatic hyperplasia

Prostate Cancer and Prostatic Diseases

Volumn 12, Issue 2, 2009, Pages 160-165

  Hammarsten, J ^a   Damber, J E ^b   Karlsson, M ^c   Knutson, T ^b   Ljunggren, O ^d   Ohlsson, C ^b   Peeker, R ^b   Smith, U ^e   Mellstrom D ^b  

^a SKARABORG HOSPITAL   (Sweden)

^b SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^c LUND UNIVERSITY   (Sweden)

^d UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^e UNIVERSITY OF GOTHENBURG   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ESTRADIOL; INSULIN;

AGED; ANTHROPOMETRY; ARTICLE; CORRELATION ANALYSIS; ENDOCRINE FUNCTION; HORMONE RELEASE; HUMAN; HYPERINSULINEMIA; LEAN BODY WEIGHT; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; ORGAN SIZE; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; RISK ASSESSMENT; RISK FACTOR; SWEDEN;

AGED; ESTRADIOL; HUMANS; INSULIN; MALE; METABOLIC SYNDROME X; PROSTATIC HYPERPLASIA; RISK FACTORS;

EID: 67349202437     PISSN: 13657852     EISSN: 14765608     Source Type: Journal    
DOI: 10.1038/pcan.2008.50     Document Type: Article

References (41)

1. Guess HA. Benign prostatic hyperplasia: Antecedents and natural history. Epidemiol Rev 1992; 14: 131-153.
2. Partin AW, Oesterling JE, Epstein JI, Horton R, Walsh P. Influence of age and endocrine factors on the volume of benign prostatic hyperplasia. J Urol 1991; 145: 405-409.
3. Walch PC, Retic AB, Stamey TA, Vaughan ED. Campbell's Urology, 6th edn. W.B. Saunders: Philadelphia, 1992, pp 1014-1015.
4. Suzuki K, Ito K, Ichinose Y, Kurokawa K, Suzuki T, Imai K et al. Endocrine environment of benign prostatic hyperplasia: Prostate size and volume are correlated with serum estrogen concentration. Scand J Urol Nephrol 1995; 29: 65-68.
5. Schatzl G, Brossner C, Schmid S, Kugler W, Roehrich M, Treu T et al Endocrine status in elderly men with lower urinary tract symptoms: correlation of age, hormonal status, and lower urinary tract function. The Prostate Study Group of the Austrian Society of Urology. Urology 2000; 55: 397-402.
6. Hammarsten J, Högstedt B, Holthuis N, Mellström D. Components of the metabolic syndrome - risk factors for the development of benign prostatic hyperplasia. Prostate Cancer Prostatic Dis 1998; 1 157-162.
7. Hammarsten J, Högstedt B. Clinical, anthropometric, metabolic and insulin profile of men with fast annual growth rates of benign prostatic hyperplasia. Blood Press 1999; 8: 29-36.
8. Hammarsten J, Högstedt B. Hyperinsulinaemia as a risk factor for developing benign prostatic hyperplasia. Eur Urol 2001; 39: 151-158.
9. Hammarsten J, Högstedt B. Calculated fast-growing benign prostatic hyperplasia - a risk factor for developing clinical prostate cancer. Scand J Urol Nephrol 2002; 36: 330-338.
10. Nandeesha H, Koner BC, Dorairajan LN, Sen SK. Hyperinsulinaemia and dyslipidaemia in non-diabetic benign prostatic hyperplasia. Clin Chim Acta 2006; 370: 89-93.
11. Ozden C, Ozdal OL, Urgancioglu G, Koyuncu H, Gokkaya S, Memis A. The correlation between metabolic syndrome and prostatic growth in patients with benign prostatic hyperplasia. Eur Urol 2007; 51: 199-206.
12. Rohrmann S, De Marzo AM, Smit E, Giovannucci E, Platz EA. Serum C-reactive protein concentration and lower urinary tract symptoms in older men in the Third National Health and Nutrition Examination Survey (NHANES III). Prostate 2005; 62: 27-33.
13. DeFronzo RA, Ferrannini E. Insulin resistance. A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care 1991; 14 173-194.
14. Dahle SE, Chokkalingam AP, Gao Y-T, Deng J, Stanczyk FZ, Hsing AW. Body size and serum levels of insulin and leptin in relation to the risk of benign prostatic hyperplasia. J Urol 2002; 168: 599-604.
15. Mellström D, Johnell O, Ljunggren Ö, Eriksson A-L, Lorentzon M, Mallmin H et al. Free testosterone is an independent predictor of BMD and prevalent fractures in elderly men: MrOS Sweden. J Bone Miner Res 2006; 4: 529-535.
16. Vermeulen A, Verdonck L, Kaufman JM. A critical evaluation of simple methods for the estimation of free testosterone in serum. J Clin Endocrinol Metab 1999; 84: 3666-3672.
17. Van den Beld AW, De Jong FH, Grobbee DE, Pols HAP, Lamberts SWJ. Measures of bioavailable serum testosterone and estradiol and their relationships with muscle strength, bone density, and body composition in elderly men. J Clin Endocrinol Metab 2000; 85: 3276-3282.
18. Littrup PJ, Williams CR, Egglin TK, Kane RA. Determination of prostate volume with transrectal US for screening - Part II. Accuracy of in vitro and in vivo techniques. Radiology 1991; 179: 49-53.
19. Terris MK, Stamey TA. Determination of prostate volume by transrectal ultrasound. J Urol 1991; 145: 984-987.
20. Giovannucci E. Nutrition, insulin, insulin-like growth factors and cancer. Horm Metab Res 2003; 35: 694-704.
21. Stattin P, Kaaks R, Riboli E, Ferrari P, Dechaud H, Hallmans G. Circulating insulin-like growth factor-I and benign prostatic hyperplasia - a prospective study. Scand J Urol Nephrol 2001; 35: 122-126.
22. Chokkalingam AP, Gao YT, Deng J, Stanczyk FZ, Sesterhenn IA, Mostofi FK et al. Insulin-like growth factors and risk of benign prostatic hyperplasia. Prostate 2002; 52: 98-105.
23. Roberts RO, Jacobson DJ, Girman CJ, Rhodes T, Klee GG, Lieber MM et al. Insulin-like growth factor I, insulin-like growth factor binding protein 3, and urologic measures of benign prostatic hyperplasia. Am J Epidemiol 2003; 157: 784-791.
24. Cohen PG. The hypogonadal-obesity cycle: Role of aromatase in modulating the testosterone-estradiol shunt - a major factor in the genesis of morbid obesity. Med Hypothesis 1999; 52: 49-51.
25. McNeal J. Pathology of benign prostatic hyperplasia: Insight into etiology. Urol Clin North Am 1990; 17: 477-486.
26. Peirson EL. A study of the effect of stilbestrol therapy on the size of the benignly hypertrophied prostate gland. J Urol 1946; 55: 73-78.
27. Campbell M, Harrison J. Urology, 6th edn. W.B. Saunders: Philadelphia, 1970, pp 1100.
28. Gingell JC, Knonagel H, Kurth KH, Tunn UW. Placebo controlled double-blind study to test the efficacy of the aromatase inhibitor atamestane in patients with benign prostatic hyperplasia not requiring operation. The Schering 90062 Study Group. J Urol 1995; 154: 399-401.
29. Radlmaier A, Eickenberg HU, Fletcher MS, Fourcade RO, Reis Santos JM, van Aubel OG et al. Estrogen reduction by aromatase inhibition for benign prostatic hyperplasia: Results of a double-blind, placebo-controlled, randomized clinical trail using two doses of the aromatase-inhibitor atamestane. Atamestane Study Group. Prostate 1996; 29: 199-208.
30. Tivesten Å, Hulthe J, Wallenfeldt K, Wikstrand J, Ohlsson C, Fagerberg B. Circulating estradiol is an independent predictor of progression of carotide artery intima-media thickness in middle-aged men. J Clin Endocrin Metab 2006; 91: 4433-4437.
31. Laaksonen DE, Niskanen L, Punnonen K, Nyyssönen K, Tuomainen T-P, Valkonen V-P et al. Sex hormones, inflammation and the metabolic syndrome: A population-based study. Eur J Endocrinol 2003; 149 601-608.
32. Laaksonen DE, Niskanen L, Punnonen K, Nyyssönen K, Tuomainen T-P, Valkonen V-P et al. Testosterone and sex hormone-binding globulin predict the metabolic syndrome and diabetes in middle-aged men. Diabetes Care 2004; 27: 1036-1041.
33. Fejes I, Koloszar S, Zavaczki Z, Daru J, Szollosi J, Pal A. Effect of body weight on testosterone/estradiol ratio in oligozoospermic patients. Arch Androl 2006; 52: 97-102.
34. Muller M, Grobbee DE, den Tonkelaar I, Lamberts SWJ, van der Schouw YT. Endogenous sex hormones and metabolic syndrome in aging men. J Clin Endocrinol Metab 2005; 90: 2618-2623.
35. Brochu M, Tchernof A, Dionne IJ, Sites CK, Eltabbakh GH, Sims EAH et al. What are the physical characteristics associated with a normal metabolic profile despite a high level of obesity in postmenopausal women? J Clin Endocrinol Metab 2001; 86: 1020-1025.
36. You T, Ryan AS, Nicklas BJ. The metabolic syndrome in obese postmenopausal women: Relationship to body composition, visceral fat, and inflammation. J Clin Endocrinol Metab 2004; 89: 5517-5522.
37. Lee S, Min HG, Choi SH, Kim YJ, Oh SW, Kim YJ et al. Central obesity as a risk factor for prostatic hyperplasia. Obesity (Silver Spring) 2006; 14: 172-179.
38. Kahn R, Buse J, Ferrannini E, Stern M. The metabolic syndrome: Time for a critical appraisal. Joint statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetolgia 2005; 48: 1684-1699.
39. Hald T. Ürodynamics in benign prostatic hyperplasia: A survey. Prostate Suppl 1989; 2: 69-77.
40. Leveillee RJ, Patel VR, Bird VG. Prostate hyperplasia, Benign. http://www.emedicine.com/med/topic1919.htm; 2004.
41. Parsons JK, Carter HB, Partin AW, Windham BG, Metter EJ, Ferrucci L et al. Metabolic factors associated with benign prostatic hyperplasia. J Clin Endocrinol Metab 2006; 91: 2562-2568.